INS and obesity due to melanocortin 4 receptor deficiency: Clinical trials in obese people with and without diabetes have shown that GLP-1RAs, the most recent anti-obesity medications approved for human use, are associated with beneficial weight-loss and metabolic improvements inclucing lower TC, TG, LDL, FPG, and insulin [27, 40–44].